欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2015, Vol. 20 ›› Issue (6): 687-693.

• 综述与讲座 • 上一篇    下一篇

华法林的药物基因组学研究及其临床应用进展

刘嘉1,王连生2   

  1. 1. 中南大学湘雅医院临床药理研究所
    2. 中南大学临床药理研究所
  • 收稿日期:2015-04-07 修回日期:2015-06-24 出版日期:2015-06-26 发布日期:2015-06-29
  • 通讯作者: 王连生 E-mail:595642156@qq.com
  • 基金资助:

    国家自然科学基金;国家863项目

Research progress on Pharmacogenetics of warfarin and clinical application

Jia LIU,liansheng wang   

  • Received:2015-04-07 Revised:2015-06-24 Online:2015-06-26 Published:2015-06-29
  • Contact: liansheng wang E-mail:595642156@qq.com

摘要: 华法林是临床上使用最广泛的抗凝药,其治疗窗窄,剂量个体差异大,很容易出现出血等不良反应。遗传因素又是影响华法林稳定剂量及不良反应最重要因素,与药效学、药代学及药物转运相关的基因都能够影响华法林的治疗。文章综述这些基因的研究现状及其临床应用的进展,旨在全面了解遗传因素对华法林治疗的影响,为临床的个体化治疗提供参考更多的依据和指导。

Abstract: Warfarin is widely used as oral anticoagulant drug with narrow therapeutic window, wide variations in dose requirements and patients easily suffer from adverse event such as bleeding. Genetic factor can significantly influence on the stability of the warfarin dose and adverse events. The genes relate of pharmacokinetics, pharmacodynamics and drug transport all can influence on warfarin therapy. The article reviews the current research status of these genes and the progress of clinical application , aiming to comprehensive understanding of the genetic factors effect on warfarin therapy, Providing reference and guidance for personalized treatment.